Neuroscience
From the FDA:
NEUROLOGICAL DEVICES PANEL OF THE MEDICAL DEVICES ADVISORY COMMITTEE (FDA)
DATE AND TIME: June 17, 8:30 a.m.
LOCATION: Hilton Washington, DC North/Gaithersburg, Salons A, B and C, 620 Perry Pkwy., Gaithersburg, MD.
CONTACT: Janet L. Scudiero, Center for Devices and Radiological Health, 301-594-1184.
Event webpage
Agenda:
The committee will hear a presentation on the FDA Critical Path Initiative and a presentation by the Office of Surveillance and Biometrics in the Center for Devices and Radiological Health outlining their responsibility for the review of postmarket study design. The committee will also hear an update on the status of recent devices brought before the committee. Subsequently, the committee will discuss, make recommendations, and vote on a premarket approval application for a selective head cooling system intended for use in infants 36 weeks of gestation or older at risk for moderate to severe hypoxic-ischemic encephalopathy (HIE) to prevent or reduce the severity of HIE.
Background material and meeting information will become available no later than one business day before the meeting (Simply scroll down to the appropriate committee heading).
Procedure:
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by June 3, 2005. Oral presentations from the public will be scheduled for approximately 30 minutes at the beginning of committee deliberations and for approximately 30 minutes near the end of the deliberations. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 3, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact AnnMarie Williams at 240-276-0450, ext. 113, at least 7 days in advance of the meeting.
Contact Person:
Janet L. Scudiero, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1184
Advisory Committee Telephone Information Line:
Please call the Information Line for up-to-date information on this meeting, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512513.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Fda Public Meeting On Computerized Cognitive Assessment
Public Workshop - Neurodiagnostics and Non-Invasive Brain Stimulation Medical Devices Workshop, November 19-20, 2015 Meeting homepage with links to agenda, background papers, and webcast streams from the meeting. [snip] "The Food and Drug Administration...
- Upcoming: Alzheimer's: Fda Advisory Committee Meeting (20-21 January 2011)
From the FDA (.pdfs of briefing material is available at the link below): January 20-21, 2011: Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement Read the full announcementAgenda "On January 20, 2011, the committee will...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the FDA: FOR IMMEDIATE RELEASE P06-25 February 16, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Allows Clinical Studies of Tysabri (natalizumab) for Treatment of MS to Proceed The Food and...
- Methylphenidate Transdermal Patch (daytrana), Adhd, & The Fda: Fda Briefing Information
Briefing Information for the FDA's psychopharmacologic drugs advisory committee meeting on Friday. - Anthony H. Risser neuroscience | neuropsychology | brain | ADHD ...
- Apply To Join The Student Government Association!
Are you interested in getting more involved in the Student Government Association? We currently have a number of open positions, ranging from two Freshman Legislator positions to Academic Legislator positions. As a legislator, you will be responsible...
Neuroscience
Upcoming Event: Gaithersburg, MD, 17 June 2005
From the FDA:
NEUROLOGICAL DEVICES PANEL OF THE MEDICAL DEVICES ADVISORY COMMITTEE (FDA)
DATE AND TIME: June 17, 8:30 a.m.
LOCATION: Hilton Washington, DC North/Gaithersburg, Salons A, B and C, 620 Perry Pkwy., Gaithersburg, MD.
CONTACT: Janet L. Scudiero, Center for Devices and Radiological Health, 301-594-1184.
Event webpage
Agenda:
The committee will hear a presentation on the FDA Critical Path Initiative and a presentation by the Office of Surveillance and Biometrics in the Center for Devices and Radiological Health outlining their responsibility for the review of postmarket study design. The committee will also hear an update on the status of recent devices brought before the committee. Subsequently, the committee will discuss, make recommendations, and vote on a premarket approval application for a selective head cooling system intended for use in infants 36 weeks of gestation or older at risk for moderate to severe hypoxic-ischemic encephalopathy (HIE) to prevent or reduce the severity of HIE.
Background material and meeting information will become available no later than one business day before the meeting (Simply scroll down to the appropriate committee heading).
Procedure:
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by June 3, 2005. Oral presentations from the public will be scheduled for approximately 30 minutes at the beginning of committee deliberations and for approximately 30 minutes near the end of the deliberations. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 3, 2005, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact AnnMarie Williams at 240-276-0450, ext. 113, at least 7 days in advance of the meeting.
Contact Person:
Janet L. Scudiero, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1184
Advisory Committee Telephone Information Line:
Please call the Information Line for up-to-date information on this meeting, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512513.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Fda Public Meeting On Computerized Cognitive Assessment
Public Workshop - Neurodiagnostics and Non-Invasive Brain Stimulation Medical Devices Workshop, November 19-20, 2015 Meeting homepage with links to agenda, background papers, and webcast streams from the meeting. [snip] "The Food and Drug Administration...
- Upcoming: Alzheimer's: Fda Advisory Committee Meeting (20-21 January 2011)
From the FDA (.pdfs of briefing material is available at the link below): January 20-21, 2011: Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement Read the full announcementAgenda "On January 20, 2011, the committee will...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the FDA: FOR IMMEDIATE RELEASE P06-25 February 16, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Allows Clinical Studies of Tysabri (natalizumab) for Treatment of MS to Proceed The Food and...
- Methylphenidate Transdermal Patch (daytrana), Adhd, & The Fda: Fda Briefing Information
Briefing Information for the FDA's psychopharmacologic drugs advisory committee meeting on Friday. - Anthony H. Risser neuroscience | neuropsychology | brain | ADHD ...
- Apply To Join The Student Government Association!
Are you interested in getting more involved in the Student Government Association? We currently have a number of open positions, ranging from two Freshman Legislator positions to Academic Legislator positions. As a legislator, you will be responsible...